



(51) International Patent Classification:

A61K 31/185 (2006.01) A61K 9/48 (2006.01)
A61K 9/20 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2012/067507

(22) International Filing Date:

2 December 2012 (02.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/566,550 2 December 2011 (02.12.2011) US
61/649,137 18 May 2012 (18.05.2012) US

(71) Applicant: SYNCHRONEURON INC. [US/US]; 9
Dover Lane, Lexington, MA 0242-6100 (US).

(72) Inventors: KERN, William D.; P.O. Box 322, Harvard,
MA 01451 (US). FOGEL, Barry S.; 9 Dover Lane, Lex-
ington, MA 0242-6100 (US). FONG, Kei-Lai; 890
Grizzly Peak Boulevard, Berkeley, CA 94708 (US).

(74) Agent: MORLEY, Marc T.; Knobbe Martens Olson &
Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA
92614 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME

Acamprosate PK in Dog: IR Capsule vs Simulated Extended Release Formulation




FIG. 1

(57) Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.